Cambridge Cognition Holdings PLC GBP1.3 million contract for a schizophrenia trial (8687T)

TIDMCOG

RNS Number : 8687T

Cambridge Cognition Holdings PLC

30 March 2021

Cambridge Cognition Holdings Plc

   (" Cambridge Cognition"   or the "Company") 

Cambridge Cognition wins GBP1.3 million cognitive assessment contract for a schizophrenia trial

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a GBP1.3 million contract as the cognitive assessment partner for a schizophrenia trial. Revenue from the contract is expected to be booked over the next three years. This is the fourth schizophrenia trial Cambridge Cognition has secured with this pharmaceutical client in seven months. The first three were announced by the Company on 1 September 2020 in a GBP2 million contract.

Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Impressed by the high degree of sensitivity CANTAB(TM) cognitive assessments demonstrate in measuring these distinct processes and the quality of service the Company delivers, Cambridge Cognition has been named as the cognitive assessment provider for the fourth trial in the series.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Schizophrenia affects more than 20 million people worldwide and we are pleased to be strengthening our relationship with a company that recognises the importance of sensitive and accurate cognitive assessment in developing effective therapeutics for the disorder. This quick succession of unusually large contracts with the same pharmaceutical company is a testament to the excellent customer experience and high-quality products Cambridge Cognition delivers."

For further information, contact:

 
 Cambridge Cognition Holdings PLC              Tel: [phone] 
  Matthew Stork, Chief Executive Officer        [e-mail] 
  Michael Holton, Chief Financial Officer 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: [phone] 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane / Charlotte Sutcliffe              (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)        Tel: [phone] 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: [phone] 
  Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTBLGDXRSDDGBC

(END) Dow Jones Newswires

March 30, 2021 02:00 ET (06:00 GMT)